Oragenics Completes Approximately $16.5 Million Offering

Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injurySARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing of its previously announced public offering of Series H Convertible Preferred Stock and Warrants. The Company secured total gross proceeds of approximately $16.5 mi ...